Dr Thomas Bachelot is careful to set reasonable expectations for his patients with HR+/HER2–metastatic breast cancer regarding how long their treatment will last and how it will impact them.
Hope Rugo, MD, discusses common presenting symptoms of HR+/HER2- metastatic breast cancer, citing bone metastasis as the most prevalent.
Sunil Verma, MD, MSEd, FRCPC discusses new classes of therapies for HR+ Breast Cancer.
Sunil Verma, MD, MSEd, FRCPC discusses treatment options for this type of cancer.
Sunil Verma, MD, MSEd, FRCPC takes up the topic of communicating with patients about what they want for their care.
Sunil Verma, MD, MSEd, FRCPC discusses all the patient factors when managing patients who relapse.
Dr Sunil Verma comments on the results of the FALCON study and how to use the data in a practical fashion to help treat patients.
Dr Thomas Bachelot discusses the potential for incorporating immunotherapy into the treatment of patients with hormone receptor–positive diseases but notes that the current data are weak, and further studies are needed to get a better sense of the viability of this treatment option.
Dr Sibylle Loibl explains how fulvestrant (with or without palbociclib) fits in the treatment paradigm for patients with HR+/ HER2-negative metastatic breast cancer.
Dr Hope Rugo discusses some of the choices and challenges she’s faced with in treating patients with HR+/ HER2-negative metastatic breast cancer with the goal of helping patients live as long as possible and with the best quality of life.